EC launches public consultation on content of site master file
This article was originally published in The Gold Sheet
Executive Summary
The European Commission is consulting the public on Part III of the EU GMPs, which describes how manufacturers should prepare site master files. The deadline for public comment is March 31. The site master file concept has been developed by the Pharmaceutical Inspection Cooperation Scheme and has become a standard expectation of EU authorities. Following a recent revision of the explanatory notes by PIC/S, it has been proposed that the status of the site master file is more formally linked to the EU regulatory framework. The site master file should contain specific information about the quality management policies and activities of the company, the production site and the quality control of pharmaceutical manufacturing operations carried out at the named site and any closely integrated operations at adjacent and nearby buildings. When submitted to a regulatory authority, the site master file "should provide clear information on the manufacturer's GMP-related activities that can be useful in general supervision and in the efficient planning and undertaking of GMP inspections.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.